Avatrombopag is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||11/02/2020|
|Rapid review completed||02/04/2020|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that avatrombopag be considered for reimbursement*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement; September 2020